- Guardant Health's (GH, Financial) Guardant Reveal test shows 100% sensitivity for distant recurrence in certain breast cancer patients.
- LIBERATE study results highlight Guardant Reveal's prognostic value for breast cancer recurrence.
- The test presents a potential shift in surveillance strategies without the need for tissue samples.
Guardant Health, Inc. (GH) has announced promising results from the LIBERATE study, published in ESMO Open, showcasing the efficacy of their Guardant Reveal test in detecting minimal residual disease (MRD) for patients with early-stage breast cancer. The study validates Guardant Reveal's high performance, demonstrating 100% sensitivity for predicting distant recurrence in patients with ER+/HER2- breast cancer, which constitutes approximately 70% of all breast cancer cases.
The LIBERATE study analyzed 290 blood samples from 95 patients who underwent chemotherapy before surgery. Guardant Reveal demonstrated a positive predictive value of 100% for relapse, with significant prognostic power for event-free survival (EFS) and a median lead time of 152 days ahead of clinical recurrence.
Guardant Reveal employs epigenomic (methylation) analysis to detect circulating tumor DNA (ctDNA) in blood samples, eliminating the need for invasive tissue samples. This feature makes it a robust tool for post-operative cancer surveillance, particularly for patients with minimal to no tumor presence post-chemotherapy.
According to Craig Eagle, M.D., Chief Medical Officer at Guardant Health, the study underscores the clinical validity and prognostic value of Guardant Reveal, potentially transforming neoadjuvant and post-treatment surveillance approaches.
Guardant Health, a pioneer in precision oncology, continues to provide critical insights through its advanced blood and tissue tests, enhancing patient care and cancer treatment strategies. For further details, visit their official website or follow them on social media platforms including LinkedIn and X (Twitter).
